Agenus partners with Gilead Sciences to develop five immuno-oncology therapies
Shares of Agenus Inc (NASDAQ:AGEN) soared Thursday as investors applauded the biotech’s new collaboration with Gilead Sciences (NASDAQ:GILD) to develop and introduce five immuno-oncology therapies.
Under the deal’s terms, Agenus, which is based in Lexington, Massachusetts, will receive a $120 million upfront payment and a $30 million equity investment from Gilead, a rival biotech in Foster City, California. The agreement also includes roughly $1.7 billion in fees and milestones that will be paid to Agenus.
In return, Gilead will receive exclusive rights to AGEN 1423, an antibody being developed by Agenus for the treatment of cancer, as well as options to license two additional T cell therapies AGEN 1223 and AGEN 2373. Gilead will also gain the right of first negotiation for two other unnamed pre-clinical programs.
In response, investors sent Agenus shares up 36% to $2.74 in Thursday’s morning session while Gilead shares held steady at $64.25.
“Our collaboration with Agenus gives us access to novel and differentiated immune modulating antibodies that will complement our growing oncology portfolio and cell therapy business. We look forward to partnering with the Agenus team,” said John McHutchison, chief scientific officer and head of research and development with Gilead Sciences.
An investigational new drug application (IND) is expected to be filed with the US Food and Drug Administration for AGEN 1423 before the end of the year while Agenus has already filed an IND for AGEN 1223. A planned IND filing for AGEN 2373 is expected in the first half of next year.
Contact Ellen Kelleher at [email protected]
Story by ProactiveInvestors
Source: https://www.proactiveinvestors.com/companies/news/211599/agenus-partners-with-gilead-sciences-to-develop-five-immuno-oncology-therapies-211599.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Lion’s Mane Mushroom
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, But it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes:
Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity.
Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins.
Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system.
Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome.
Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function.
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules. Today Be 100% Satisfied Or Receive A Full Money Back Guarantee Order Yours Today By Following This Link.
| Online: | |
| Visits: | 1,608,067,971 |
| Stories: | 8,163,542 |
Whistler Blowers, Insiders
